Cellectar reports 94% reduction in overall tumor volume in phase 2 CLR 131 clinical study
Cellectar Biosciences announces that a patient in the lymphoplasmacytic lymphoma arm with advanced Waldenstrom macroglobulinemia, enrolled in the CLR 131 Phase 2 trial, showed a 94% reduction in tumor burden and complete resolution in four of five targeted tumor masses. July 17, 2018